Wire · operational-macro
China's Innovative Pharmaceuticals Gain Momentum
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
China's pharmaceutical sector is rapidly growing in innovative drug development, securing a record number of global licensing deals worth approximately $110 billion in 2026, attracting major international pharmaceutical companies. This surge highlights China's competitive position as a cost-efficient and innovative alternative for late-stage clinical trials and drug licensing, especially in oncology and other key therapeutic fields.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You need to treat China as a core source for innovative pharmaceutical collaboration, not just a manufacturing base. Big drug companies like Merck and Eli Lilly are proving you can accelerate development at lower cost there, opening a direct route to global markets.
◆ Coverage
1 source · 21 Sep 2026
◆ Related on Wire
◆ Topics